NICE in UK refuses to recommend crizotinib for ROS1+ NSCLC

Last week the National Institute for Health and Care Excellence (NICE) decided not to recommend Xalkori for the treatment of ROS-positive non-small cell lung cancer in the United Kingdom. More information here:

NICE Appraisal Consultation Document

NICE shoots down Pfizer’s Xalkori in ROS1-positive patients, inviting a CDF proposal instead (from Fierce Biotech)

Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.

One thought on “NICE in UK refuses to recommend crizotinib for ROS1+ NSCLC

Comments are closed.